What is denosumab?

Also known as denosumab, it is a powerful and effective bone resorption inhibitor and a targeted treatment drug for osteoporosis that targets the osteoclast regulatory pathway. Keaveny et al. used denosumab to treat postmenopausal osteoporosis patients and used quantitative CT to conduct limited $ analysis on the bone strength of cortical and cancellous bones. The results showed that the bone strength of cortical and cancellous bones increased significantly in the denosumab treatment group.

Bone metastasis is one of the most common metastasis sites of cancer and is widely found in many cancer types such as breast cancer, lung cancer, prostate cancer, and uterine cancer. Data show that about 65%-75% of patients with advanced breast cancer will develop bone metastasis, while among patients with lung cancer, this number is about 30%-40%, accounting for more than one-third. In fact, secondary cancer that metastasizes to bone tissue is difficult to cure, but people can still reduce symptoms and prolong survival through standard treatment.

Suzuki et al. treated 25 postmenopausal osteoporosis patients who did not receive bisphosphonates and 24 patients who had long-term bisphosphonate treatment with denosumab for 3 years. The results showed that compared with before treatment, the bone mineral density of the lumbar spine and femoral neck in each group increased. The degree was increased compared with before treatment, and the increase was more obvious in the group that did not receive bisphosphonate treatment. The bone turnover markers decreased more significantly than before treatment, indicating that denosumab has a more significant effect on patients with osteoporosis who have not received treatment and is a first-line drug for the treatment of osteoporosis. Chen et al. studied the pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of denosumab (denosumab): A randomized, single-blind, placebo-controlled study showed that denosumab 60 mg and 120 mg were well tolerated. No new safety issues were found in healthy Chinese subjects, and its pharmacokinetic and pharmacodynamic characteristics were similar to those of Caucasians. For the prevention and treatment of osteoporosis, it only needs to be injected subcutaneously once every six months at a dose of 60 mg. The medication interval is long, the administration method is simple, and it is an efficient treatment plan, making it easier for patients to accept.